how much of bristol myers squib annual revenue is eliquis

Eliquis appears to make up roughly about one-fifth to one-quarter of Bristol Myers Squibb’s annual revenue, based on 2025 company revenue of about $48.2 billion and recent reporting that Eliquis sales are projected to be in the low-to-mid teens billions range, though the exact share varies by year and exchange-rate assumptions.

Rough share

• If Eliquis sales are around $12 billion , that is about 25% of $48.2 billion.
• If Eliquis sales are around $10 billion , that is about 21% of $48.2 billion.
• So a practical estimate is ~20% to 25% of annual revenue.

Why it varies

Eliquis is co-marketed with Pfizer, so analysts often discuss global sales rather than Bristol Myers Squibb’s full booked share, which makes the revenue contribution harder to pin down precisely from headline figures alone.

Also, 2026 expectations point to declining Eliquis sales as European patent expiry pressures the product, so its revenue share may fall over time even if BMS total revenue stays similar.

Quick takeaway

In plain English, Eliquis is still one of Bristol Myers Squibb’s biggest single products, but it is not the majority of the company’s business. A good rule of thumb is that it contributes around a quarter of annual revenue, give or take.